Articles Published in 2013

MPI Research breaks ground on Imaging Center

Friday, September 6, 2013 03:04 PM

MPI Research, in partnership with INVICRO, which has a range of imaging services and software solutions, and 3D Imaging, has broken ground on its new imaging center, set to open next spring at MPI Research’s corporate headquarters in Mattawan, Mich.

More... »

Clintrak launches digital labeling service The DigiPly

Friday, September 6, 2013 03:03 PM

Clintrak, a clinical trial label company, has launched The DigiPly, a digital label service with benefits including enhanced turnaround times, quality control and flexible label options.

More... »

Otsuka to acquire Astex Pharmaceuticals

Friday, September 6, 2013 03:00 PM

Otsuka Pharmaceuticals will acquire Astex Pharmaceuticals for approximately $886 million, through a tender offer for all outstanding Astex shares expected to close in the fourth quarter.

More... »

Sanofi, Pozen ink exclusive license agreement

Friday, September 6, 2013 02:59 PM

Sanofi and Pozen, a pharmaceutical company specializing in developing novel therapeutics for unmet medical needs and licensing those products to other pharmaceutical companies for commercialization, have announced an exclusive license agreement for commercialization of Pozen's proprietary, investigational, coordinated-delivery tablets combining immediate-release omeprazole, a proton pump inhibitor (PPI), and enteric-coated (EC) aspirin in a single tablet (PA), PA8140 and PA32540. Sanofi will have exclusive rights to commercialize all PA combinations that contain 325mg or less of enteric-coated aspirin in the U.S. Pozen will receive an upfront payment of $15 million and will be eligible for pre-commercial milestone payments of up to $20 million and other future milestone payments and royalties on product sales. 

More... »

ThromboGenics acquires exclusive rights from Bicycle Therapeutics

Friday, September 6, 2013 02:57 PM

ThromboGenics, a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, has entered into a collaboration and license agreement with Bicycle Therapeutics to develop and commercialize novel drugs inhibiting a specific target for the treatment of ophthalmic diseases, such as diabetic macular edema (DME).

More... »

The Clinical Trial Company opens new California office

Friday, September 6, 2013 02:56 PM

The Clinical Trial Company (TCTC), headquartered in the U.K., has incorporated a new U.S. business to meet the growing number of U.S. clients and sponsors, in the San Francisco Bay area.

More... »

Thermo Fisher Scientific, Siemens renew partnership

Friday, September 6, 2013 02:55 PM

Thermo Fisher and Siemens Healthcare Diagnostics have renewed their non-exclusive, long-term, royalty-bearing agreement for the use of Thermo Fisher’s Procalcitonin (B·R·A·H·M·S PCT) technology, currently available as an automated immunoassay on the Siemens ADVIA Centaur XP and CP systems in all countries outside the U.S. and China. The agreement extends a long-standing relationship between the companies.

More... »

EMA now accepting Safe-BioPharma digital signatures on eSubmissions

Friday, September 6, 2013 02:53 PM

Beginning this month, SAFE-BioPharma digital signatures will be accepted by the European Medicines Agency (EMA).  

More... »

Arthritis Research U.K., MS Society to award $10 million in research grants

Friday, September 6, 2013 02:52 PM

Arthritis Research U.K. and the MS Societyare partnering three research councils in the second stage of a nationwide project, which will see $10 million made available to researchers in stem cell and tissue engineering research.

More... »

CenterWatch launches new version of Clinical Trials Listing Service

Friday, September 6, 2013 02:51 PM

CenterWatch, a publisher of clinical trials information for patients and professionals, has launched a revamped version of its award-winning Clinical Trials Listing Service (CTLS) to better serve the public and patient communities. 

More... »